

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 July 2002 (18.07.2002)

PCT

(10) International Publication Number
WO 02/055069 A1

(51) International Patent Classification⁷: **A61K 31/205**,
A61P 9/12

MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/FI02/00024

(22) International Filing Date: 11 January 2002 (11.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20010075 12 January 2001 (12.01.2001) FI

(71) Applicant (for all designated States except US): **FINN-
FEEDS FINLAND LTD** [FI/FI]; Keilaranta 9, FIN-02150
Espoo (FI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TÖRRÖNEN, An-
neli** [FI/FI]; Pohjoiskaari 13 A 2, FIN-00200 Helsinki (FI).
JUTILA, Kirsti [FI/FI]; Rantapolku 2 B 10, FIN-02170
Espoo (FI). **UUSITUPA, Matti** [FI/FI]; Vällilahdentie 10,
FIN-70260 Kuopio (FI). **SCHWAB, Ursula** [FI/FI]; Orsi-
tie 9 B 7, FIN-70820 Kuopio (FI).

(74) Agent: **KOLSTER OY AB**; Iso Roobertinkatu 23, P.O.
Box 148, FIN-00121 Helsinki (FI).

(81) Designated States (national): AE, AG, AL, AM, AT, AT
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE
(utility model), DK, DK (utility model), DM, DZ, EC, EE,
EE (utility model), ES, FI, FI (utility model), GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS,
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI,
CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **USE OF BETAININE IN FUNCTIONAL PRODUCTS HAVING BLOOD PRESSURE LOWERING EFFECTS**

(57) Abstract: The present invention relates to the use of betaine in functional products, such as pharmaceutical products, functional food products, food supplements, natural products and the like. In particular, the present invention relates to the use of betaine for the manufacture of functional products having blood pressure lowering effects, and to methods for lowering blood pressure.

BEST AVAILABLE COPY

WO 02/055069 A1

USE OF BETAINES IN FUNCTIONAL PRODUCTS HAVING BLOOD PRESSURE LOWERING EFFECTS

Field of the invention

The present invention relates to the use of betaine in functional products, such as pharmaceutical products, functional food products, food supplements, natural products and the like. In particular, the present invention relates to the use of betaine in functional products having blood pressure lowering effects, and to methods for lowering blood pressure.

Background of the invention

Betaine has been reported to both improve gut health and to increase the food intake and growth of animals. Betaine has also been found to decrease the body fat of for example fish, chicks, piglets and growing pigs (see e.g. Virtanen, E. et al., Effects of food containing betaine/amino acid additive on the osmotic adaption of young Atlantic Salmon, *Salmo salar* L. Aquaculture 83 (1989) 109-112; Saundersson, C.L. and McKinlay, J., Changes in body weight, composition and hepatic enzyme activities in response to dietary methionine, betaine and choline levels in growing chicks, *British J. Nutrition* 63 (1990) 339-349; and Virtanen, E. and Campbell, R., Reduzierung der Rückenspeckdicke durch Einsatz von Betain bei Mastschweinen (Reduction of backfat thickness through betaine supplementation of diets for fattening pigs). Handbuch der tierischer Veredlung. Verlag H. Kamlage, Osnabruck, Deutschland, 19 (1994) 145-150).

Betaine has also been reported to have pharmacological effects in animals. For example proline betaine has been reported to prevent perosis in chicks and glycine betaine has been reported to prevent the detrimental effects of coccidiosis in broilers (PCT/FI94/00166). Betaine has also been reported to enhance the reproductive performance of animals (PCT/FI96/00211).

In man, betaine has been reported to reduce increased blood homocysteine levels in patients suffering from any of the three primary types of homocysteinuria (see e.g. Wilcken, D.E.L., Dudman, N.P.B. and Tyrrell, P.A., Homocystinuria Due to Cystathionine β -Synthase Deficiency - The Effects of Betaine Treatment in Pyridoxine-Responsive Patients. *Metabolism* 34 (1985) 12:1115-1121; Surtees, R., Bowron, A., Leonard, J. *Pediatr Res.* 42 (1997) 577-582). The effect of betaine on plasma homocysteine levels in healthy subjects has also been studied (Brouwer, I.A. and Urgert, B. Betaine Supplementation on Plasma Homocysteine in Healthy Volunteers. *Arch. Intern Med* 160 (2000)

2546-2547). The positive effect of betaine on the methionine level and transamination thereof has been reported by A. Tangerman et al. (Tangerman, A., Wilcken, B, Levy, H.L., Boers, G.H.J., and Mudd, S.H. Methionine Transamination in Patients With Homocystinuria Due to Cystathionine β -
5 Syntase Deficiency. *Metabolism* 49 (2000) 8:1071-1077).

A betaine preparation for the treatment of homocystinuria is commercially available under the trademark Cystadane, Orphan Medical Inc., Minnetonka, MN 55305. The product consists of anhydrous betaine as a white, granular, hygroscopic powder which is easily soluble in water. For use,
10 prescribed amount of the powder is added to water, mixed until completely dissolved, and then immediately orally consumed (Orphan Medical Inc., 13911 Ridgedale Drive, Suite 475, Minnetonka, MN 55305, Cyst 06, revised 1196). Other pharmaceutical preparations for reducing homocysteine levels, and optionally containing betaine as one of the ingredients, are described e.g. in WO
15 00/44385, Bogye Gabor, and EP 0 595 005 A1, Vesta Medicines Ltd.

A pharmaceutical preparation for the treatment and prevention of transmethylation disorders, such as cardiovascular diseases, is described in WO 00/25764, Merck G.m.b.H. The composition preferably comprises three different active components, namely a methyl or methylene donor, a methyl
20 transporter, and a bioflavonoid. As an example, a composition containing betaine 600 mg, Ca L-5-methyltetrahydrofolate 0.5 mg and isoquercetin 500 mg, is described.

Betaine has also been reported to be useful in treating hepatopathies, in particular fatty liver (Babucke, G. and Sarre, H. Klinische
25 Erfahrungen mit Betaincitrat. *Med. Klin.* 68 (1973) 1109-1113). Betaine has also been suggested to decrease the concentration of serum triglycerides and blood alcohol. However, there are no controlled studies regarding these issues.

RU 2105509, Dal'nevostochnyj kommercheskij institut, describes a beetroot juice called "Red Beet Rose". The juice contains sugar syrup, citric
30 acid, and juice from the top parts of beetroots. For preparation of the juice, top parts of beetroot are washed, treated with steam in 105 C, ground and pressed. The pressed juice is filtered and mixed with sugar syrup and citric acid. The advantage of the described invention is that the top parts of beetroots, which according to the publication earlier have been regarded as waste material, now
35 can be utilized and thus the assortment of vegetable juices be broadened, and a product with beautiful cherry colour obtained.

High blood pressure, or hypertension, is one of the most common diseases in developed countries. High blood pressure is defined as a consistent recording of systolic blood pressure of 140 mmHg or higher, diastolic blood pressure of 90 mmHg or higher. The two main factors influencing blood pressure are the peripheral resistance, i.e. the width of the arteries into which the blood is being pumped, and the cardiac minute volume, i.e. the amount of blood the heart pumps. However, blood pressure is very complicatedly regulated and many other factors also play an important role.

Most people having high blood pressure have primary or essential hypertension where the etiology is unknown and lifestyle factors play a significant role. Only a small number of cases of high blood pressure are caused by other illnesses, such as kidney disease or hormonal imbalance (secondary hypertension).

Clinical trials have shown that reductions in elevated blood pressure of about 10-12 mmHg systolic and 5-6 mmHg diastolic conferred relative reductions in stroke risk of 38% and in risk of coronary heart disease of 16% (Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. *Br Med Bull* 50 (1994) 272-98). Hypertensive patients are commonly treated with diuretics, β -blockers, calcium antagonists and ACE (angiotensin converting enzyme) inhibitors. The treatment is chosen individually and is always kept under doctors control. As an alternative to medication, or in addition thereto, other methods to lower elevated blood pressure levels have been investigated, and nowadays the main aim is to prevent that the blood pressure raises to a level where medication is needed. Lifestyle factors and daily diet play an important role in the pathogenesis of essential hypertension. Thus, the blood pressure lowering effects of dietary components are under intensive investigation. The use of functional foods as a part of the normal diet, for maintaining a normal blood pressure, would be an appreciated alternative for the consumers.

In the literature of the art it is traditionally known that peptide like products may reduce blood pressure. E.g. taurine is known to lower blood pressure in essential hypertension and some experimental hypertensive models (Harada, H., Kitazaki, K., Tsujino, T., Watari, Y., Iwata, S., Nonaka, H., Hayashi, T., Takeshita, T., Morimoto, K., Yokoyama, M. Oral taurine supplementation prevents the development of ethanol-induced hypertension in rats. *Hypertens Res* 23 (2000) 3:277-284). Arginine also seems to lower blood pressure and

In accordance with the present invention, it has been shown that betaine lowers the diastolic blood pressure, in particular.

Detailed description of the invention

The present invention is based on the finding that betaine has a very
5 beneficial lowering effect on blood pressure, and in particular on the diastolic pressure.

Betaine refers to fully N-methylated amino acids. Betaines are natural products that have an important function in both plant and animal metabolism. One of the most abundant betaines is a glycine derivative in which three methyl
10 groups are attached to the nitrogen atom of the glycine molecule. This betaine compound is usually called betaine, glycinebetaine, trimethylglycine or trimethyl-ammonium acetate, and it has the following structural formula:



(anhydride)

Other betaines include, for example, alanine betaine, proline betaine and histidine betaine. A detailed description of betaines is given by Wyn Jones, R.G. and Storey, R. in *The physiology and Biochemistry of Drought Resistance in Plants*, ed. Paleg, L.G. and Aspinall, D. Academic Press, Sydney, Australia,
25 1981, which is incorporated herein by reference.

Betaine thus have a bipolar structure and it contains several chemically reactive methyl groups, which it can donate in enzyme-catalyzed reactions. Most organisms are able to synthesize small quantities of betaine e.g. for the methyl function, but they are not able to produce and store large
30 quantities of betaine. The best known organisms that accumulate betaine are plants of the genus *Chenopodiaceae*, such as sugar beet, and some microbes and marine invertebrates. Probably the main reason for these organisms to store betaine is that betaine functions as an osmolyte and thereby protects the cells from the effects of osmotic stress. Betaine has also been observed to
35 stabilize the operation of macromolecules in cell membranes.

Human cells also contain betaine. In the human body, betaine likewise is involved in methionine metabolism: it donates a methyl group to homocysteine, which in turn turns to methionine. The amount of betaine in different organs vary a lot, high amounts are present e.g. in Kupfer cells in the liver and in kidney cells, and betaine is present both in blood and in urine. In plasma from healthy humans, the betaine concentration is about 20-60 $\mu\text{mol/l}$, the concentration being considerable higher in adult males than in adult females. In urine, the betaine concentration is significantly high in neonatals and children under 12 months old, the concentration decreasing, after an initial sharp decline, steadily during childhood (Lever, M., Sizeland, P.C.B., Bason, L.M., Hayman, C.M. and Chambers, S.T. Glycine betaine and proline betaine in human blood and urine. *Biochimica et Biophysica Acta* 1200 (1994) 259-264).

Betaine is thus a compound naturally occurring in human cells, and it is part of our normal diet, present in foods such as sugar beet, spinach, and seafood, in particular molluscs and crustacean.

Betaine has been safely used in animal feed for over 25 years. Betaine was first used in fish feeds, for salmon and trout, as an attractant and an osmoprotectant during the freshwater/seawater transfer stage (Virtanen et al., 1989, supra). Its use has developed in the last 10 years as an additive for poultry and pig feed as a methyl donor and osmoprotectant. Some studies have indicated that betaine is able to decrease the amount of fat tissue in pigs without affecting the amount of lean tissue (Virtanen and Campbell, 1994, supra).

Betaine also has been used for several years in the treatment of homocystinuria, and has been demonstrated to be safe, also for use in pediatrics, and without severe adverse effects.

Betaine can be obtained, for example, from sugar beet by chromatographic methods (see e.g. WO 97/45185, Cultor Ltd., and the description of the background art given therein, particularly on p. 4, l. 9 - 26; EP 54544 Suomen Sokeri Oy; EP 345511, Suomen Sokeri Oy). Alternatively, betaine can be prepared synthetically, by using organic synthesis, biosynthesis or genetechology. Suitable synthesis routes are described e.g. in WO 00/11142, Cultor Corporation. Betaine is commercially available from Finnfeeds Finland Ltd. Betaine products, such as anhydrous, monohydrate, hydrochloride and concentrated betaine solutions, are also available and can be used in the way described in the current document. Other betaine salts and derivatives can

also be used. As examples may be mentioned, in a non-exclusive manner, betaine glutamate or betaine citrate.

Preferably, the betaine product is prepared by chromatographic methods, and, when desired, converted into a salt or derivative. Sugar beet
5 contains about 0.20% glycine betaine and is regarded as the most preferred starting material for betaine production.

For use in accordance with the present invention, betaine or a salt thereof is administered to the subject as such or as a component of a pharmaceutical product, a food product, a food supplement, a dietary
10 supplement or a natural product. Preferred administration forms include, but are not limited to, pills, capsules, dry powders, granulates, and liquid formulas. Betaine is readily dissolved in water or beverages of any kind, such as fruit juices, vegetable juices, nectars, milk products, soft drinks, coffee or tea, beer and other alcoholic drinks, etc. It can also be used in dry form e.g. in milk
15 powder, or instant coffee, tea or cocoa. Another major product group comprises salt and sweet snacks of any kind, peanuts, energy bars, hard candy, liquorice sticks and powders, ammonium chloride in liquid, powder or pastille form, confectionery, cookies, chewing gums, dried products, such as dried fruits, vegetables, raisins, and the like. For use in the preparation of pharmaceutical
20 products, food products, dietary additives, and natural products, betaine in the form of dried powder, granulate or (water) solution is considered as preferred; in these forms, it is easily added to the final product either during or after the preparation thereof.

In connection with the present invention, the term food is broadly
25 construed, including any edible products which can be in a liquid to solid form, and covering both ready-to-eat products and products to which the product of the invention is added in connection with consumption, as a supplement or to be a constituent of the product. For instance, foods can be products of beverage industry, confectionery industry, food processing industry, meat processing
30 industry, fish processing industry, baking industry, and dairy industry. As mentioned above, beverages and snack products are regarded as preferred.

The final products comprising betaine as a blood pressure lowering substance in accordance with the present invention may thus include, in addition to the betaine, ingredients normally used in such products, and they are
35 prepared according to methods conventionally used in pharmaceutical industry,

and food and dietary supplements industry, including beverages and functional products.

Betaine is used in an amount sufficient to achieve the desired, blood pressure maintaining or lowering effect. The amount can vary within a large range, depending e.g. on the health, age, and medication of the subject, and can easily be determined by the physician after the publication of the invention. Suitable added amounts may be e.g. about 0.05 - 20 g betaine per day. Betaine amounts of 0.1-8 g per day, in particular 0.5-6 g per day, are regarded as preferred.

In accordance with the present invention, it has been shown that betaine lowers the blood pressure. The examples show that a significant reduction in blood pressure is achieved. Furthermore, the diastolic pressure, in particular, is lowered. This is an important finding, bearing in mind that most pharmaceutical products presently on the market mainly lower the systolic blood pressure.

It should also be noted that betaine exerts its blood pressure lowering effect even in normotensic subjects, i.e. people with normal blood pressure. The blood pressure lowering effect of betaine is expected to be even more significant in hypertensive subjects. It is also believed that betaine has favourable effects for instance on the oral mucosa, in prevention of cardiovascular disease, as liver protectant, and as osmoprotectant in the kidneys. Betaine is thus suitable for use both as a pharmaceutical agent and as a functional agent having beneficial effects on our overall well-being.

Significantly increased amounts of betaine were found in the blood and urine of the persons given betaine in the study. This finding indicates that betaine is absorbed and secreted through the kidneys. There was, however, no clear correlation between blood and urine betaine levels. After administration of 1, 3 or 6 g betaine an amount of about 3, 5 and 7%, respectively, was recovered as betaine and dimethylglycine (DMG) in 24 h urine. After loading betaine 100 mg/kg, peak serum concentrations were found 1-2 h after loading; the concentrations varying a lot with individual (148-258 $\mu\text{mol/l}$).

The invention will be described in greater detail by means of the following examples. The examples are only provided in order to illustrate the invention and they should not be construed to restrict the scope of invention in any way.

Example

The effects of betaine supplementation on blood pressure, and in addition on body weight, body composition, resting energy expenditure, and concentrations of serum total and lipoprotein lipids and plasma homocysteine in humans, were studied. The participants were healthy, obese adults with normal blood pressure.

Forty-two subjects (14 males, 28 females) without any chronic disease and with normal liver, kidney and thyroid function participated in the study. The inclusion criteria for body mass index (BMI) was 28-40 kg/m² and for age 25-60 years. Serum concentration of total triglycerides had to be <3.5 mmol/l and that of total cholesterol <7.5 mmol/l. Inclusion criteria for fasting concentration of plasma glucose was <6.7 mmol/l. Subjects with lipid lowering medication were excluded as well women with perimenopause. Four women were postmenopausal in the control group and 6 were postmenopausal in the betaine group. None of the participants were on a medication for hypertension.

The subjects were not allowed to use nutrient supplements during the study or one month before the study.

Study design

The study was a controlled, randomized double-blinded parallel study. Before the 12-week intervention period the subjects had a 4-week run-in period during which they consumed 1 dl/d orange juice with 6 g grapefruit juice per 1 dl orange juice twice a day (1 dl in the morning, 1 dl in the evening). Grapefruit juice was added to simulate the bitter taste of betaine. The subjects were on their regular eucaloric diet during this period. For the intervention period with an hypocaloric (-2100 kJ or -500 kcal) diet the subjects were randomly assigned in two groups (20 for the control group, 22 for the betaine group). The subjects were matched for BMI, gender and menstrual cycle.

The control group consumed orange juice 1 dl twice a day and the betaine group consumed betaine enriched orange juice 1 dl twice a day. The amount of betaine was 3 g per 1 dl orange juice, giving a daily betaine dose of 6 g.

Statistical analyses

The data were analyzed with the SPSS/PC+ statistics program (V8.0, SPSS; Chicago, IL). Before further analyses, normal distribution of the variables was checked with the Kolmogorov-Smirnov test with Lilliefors significance correction. Variables with abnormal distribution (TG) were logarithmized and the

logarithmized values were used in further analyses. GLM for repeated measures was used to test the changes within time. In cases the result of this analysis was significant paired t-test was used for two-tailed comparisons within the groups. Student's t-test was used for between-group comparisons. Mann-Whitney's U-test and Wilcoxon matched-pairs signed-ranks test, respectively, were used to test the changes in lean body mass as kg, lean body mass as percent and fat mass as percent measured by bioelectric impedance since the distribution of these variables did not turn to normal by logarithmization or other arithmetic procedures. All data are expressed as mean \pm SD.

10 **Effect of betaine on blood pressure**

Blood pressure was measured from the right arm after five minutes of rest in sitting position using a zero mercury sphygmomanometer. Two measurements were performed and the mean of them was calculated and used for further analyses.

15 The results are presented in tables 1 and 2. The blood pressure, especially the diastolic blood pressure decreased significantly in the betaine group (Table 1). The results thus clearly show the effect of betaine on diastolic blood pressure reduction even in normotensive subjects; it is expected that the effect is even more significant in (mildly) hypertensive subjects.

Table 1. Blood pressure at the beginning (4 wk) and at the end (16 wk) of the intervention period

5	Control group			
	4 wk	16 wk	P-value	
	Blood pressure (mmHg)			
	Systolic	127.4 ± 17.5	126.8 ± 18.1	0.693
	Diastolic	86.1 ± 10.8	83.7 ± 11.7	0.110
10				
	Betaine group			
	4 wk	16 wk	P-value	
15	Blood pressure (mmHg)			
	Systolic	122.5 ± 9.5	121.1 ± 9.4	0.432
	Diastolic	85.4 ± 7.9	80.5 ± 7.1	0.002
20	Mean ± SD.			

Table 2. Change in blood pressure during the intervention period.

25		Control group	Betaine group	P-value
	Blood pressure (mmHg)			
	Systolic	-0.6 ± 6.7	-1.4 ± 8.0	0.740
	Diastolic	-2.4 ± 6.4	-4.9 ± 6.6	0.219
30	Mean + SD.			

Body weight was measured using the same calibrated electronic scale throughout the study. Body composition was measured by a bioelectric impedance (BIA 101S with Bodygram software, Akern S.r.l. Biosearch, Italy).

The results are presented in table 3.

When changes in the above mentioned variables during the intervention period were compared between the groups no significant differences were found (table 4). The results thus seems to be due to the

lower calory intake, and not to betaine intake. This result confirms that the blood pressure lowering effect stems from betaine intake, and not from an overall weight reduction effect.

5 **Table 3. Body weight, and BMI at the beginning (4 wk) and at the end (16 wk) of the intervention period**

		Control group		P-value
		4 wk	16 wk	
10	Body weight (kg)	94.6 \pm 9.9	91.1 \pm 8.7	0.001
	BMI (kg/m ²)	33.2 \pm 3.2	32.1 \pm 3.0	0.001

		Betaine group		P-value
		4 wk	16 wk	
15	Body weight (kg)	95.7 \pm 11.3	93.5 \pm 11.1	0.004
	BMI (kg/m ²)	33.5 \pm 3.2	32.8 \pm 3.7	0.005

20

Table 4. Change in body weight and BMI in the intervention period.

		Control group	Betaine group	P-value
	Body weight (kg)	-3.4 \pm 4.1	-2.2 \pm 3.2	0.303
25	BMI (kg/m ²)	-1.2 \pm 1.3	-0.7 \pm 1.1	0.230

Plasma total homocysteine was determined by a modification of the highpressure liquid chromatographic method described by Ubbink et al. (Ubbink, J.B., Vermaak, W.J.H., Bissbort, S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. *J Chromatogr* (1991) 565:441-446). The modified mobile phase consisted of 0.37 mol/l acetate and 0.5 % methanol, pH 4.15.

Folate concentration of plasma and erythrocytes was determined by the fluorescence polarization immunometric Imx-method (Abbott Laboratories, IL).

Serum normal homocysteine concentration ($< 15 \mu\text{mol/l}$) decreased significantly in the betaine group (8.76 ± 1.63 vs. 7.93 ± 1.52 , 4 wk vs. 16 wk, $P = 0.025$). In the control group it did not change (8.01 ± 2.47 vs. 8.12 ± 2.25 , $P = \text{N.S.}$). The change in serum homocysteine concentration during the intervention period was also significantly different between groups (0.17 ± 0.27 vs. -0.83 ± 0.34 , $P = 0.030$). Fasting plasma folate concentrations did not change during the study in either of the groups whereas the folate concentration in erythrocytes decreased significantly ($P = 0.024$) in the betaine group but did not change in the control group. Thus, the serum or erythrocyte folate levels of the subjects did not cause the homocysteine lowering effect. Consequently, the advantageous effect of betaine alone on the homocysteine level has been clearly proved in connection with the present invention.

The study also showed that the 6g daily dose was well tolerated and no side effects were observed.

Claims

1. Use of glycine betaine for the manufacture of a product for reducing blood pressure.
- 5 2. Use according to claim 1, wherein the blood pressure is normotensic.
3. Use according to claim 1, wherein the blood pressure is hypertensic.
4. Use of glycine betaine for the manufacture of a product for the
- 10 treatment or prevention of hypertension.
5. Use according to any of claims 1-4, wherein a daily dosage of 0.05-20 g of added glycine betaine is provided.
6. Use according to claim 5, wherein a daily dosage of 0.1-8 g per day, preferably 0.5-6 g per day of added glycine betaine is provided.
- 15 7. Use according to any of claims 1-6, wherein the glycine betaine is in the form of anhydride, monohydrate, or a salt.
8. Use according to any one of claims 1 - 7, wherein the glycine betaine is prepared synthetically or by chromatographic separation.
9. Use according to claim 8, wherein the glycine betaine is
- 20 converted into a salt or derivative.
10. Use according to any one of claims 1 - 9, wherein the manufactured product reduces diastolic pressure.
11. Use according to any one of claims 1 - 9, wherein the product is a pharmaceutical product, a food product, a food supplement, a dietary
- 25 supplement, a natural product or another functional, edible product.
12. Use according to claim 11, wherein the product is a functional food product.
13. Method for maintaining normal blood pressure, comprising administering to a subject glycine betaine in an amount sufficient to
- 30 achieve the desired result.
14. Method for reducing blood pressure, comprising administering to a subject glycine betaine in an amount sufficient to achieve the desired result.
15. Method for the prevention or treatment of hypertension,
- 35 comprising administering to a subject in need of such treatment glycine betaine in an amount sufficient to achieve the desired result.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 02/00024

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 31/205, A61P 9/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, A23L, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI DATA, EPO-INTERNAL, PAJ, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Journal of Medicinal Plant Research, Volume 34, 1978, Mitsuru Tamada et al: "Maakonine, Hypertensive Principle of Ephedra Roots", page 291 - page 293 --	1-15
X	European Journal of Pharmacology, Volume 342, 1998, Hana Rauchová et al: "The Effect of chronic L-carnitine treatment on blood pressure and plasma lipids in spontaneously hypertensive rats", page 235 - page 239 --	1-15
X	WPI/Derwent's abstract, Accession Number 1985-239349, week 8539, ABSTRACT OF JP, 60155115 (JAPAN HOSPITAL SUPP) 15 August 1985 (15.08.85) --	1-15

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

30 April 2002

Date of mailing of the international search report

14-05-2002

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Anna Sjölund/Eö
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 02/00024

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WPI Derwent's abstract, Accession Number 1996-222359, week 9622, ABSTRACT OF ZA, 9503839 (BURGER A) 27 March 1996 (27.03.96) --	1-15
X	US 5859056 A (IVARS KALVINSH ET AL), 12 January 1999 (12.01.99) --	1-15
X	US 4663348 A (LESTER CHAFETZ ET AL), 5 May 1987 (05.05.87) --	1-15
X	US 3090725 A (FREDERICK CHARLES COPP ET AL), 21 May 1963 (21.05.63) --	1-15
X	US 5126291 A (ALLAN WISSNER), 30 June 1992 (30.06.92) --	1-15
X	BE 1012546 A6 (LE MINISTRE DES AFFAIRES ECONOMIQUES), 5 December 2000 (05.12.00) --	1-15
X	WO 0100047 A1 (THE NEW ZEALAND MILK INSTITUTE LIMITED), 4 January 2001 (04.01.01) --	1-15
X	WO 0025764 A2 (MERCK PATENT GMBH), 11 May 2000 (11.05.00) --	1-15
X	EP 0781554 A1 (TAIHO PHARMACEUTICAL CO., LTD.), 2 July 1997 (02.07.97) -- -----	1-15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/FI02/00024

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **13-15**
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/FI02/00024

Claims 13-15 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT
Information on patent family members

28/01/02

International application No.
PCT/FI 02/00024

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
US	5859056	A	12/01/99	CA	2229228 A	27/02/97
				EP	0845986 A	10/06/98
				JP	3072858 B	07/08/00
				JP	10512286 T	24/11/98
				LV	11728 A,B	20/04/97
				WO	9706794 A	27/02/97
US	4663348	A	05/05/87	AU	599034 B	12/07/90
				AU	5889086 A	08/01/87
				BE	904986 A	24/12/86
				CH	670448 A	15/06/89
				DE	3619665 A	08/01/87
				DK	312586 A	03/01/87
				FR	2584405 A,B	09/01/87
				GB	2189239 A,B	21/10/87
				GB	8615275 D	00/00/00
				IT	1191972 B	31/03/88
				IT	8648183 D	00/00/00
				JP	62005975 A	12/01/87
				LU	86484 A	02/12/86
				NL	8601519 A	02/02/87
				SE	8602917 A	03/01/87
				ZA	8604207 A	25/02/87
US	3090725	A	21/05/63	NONE		
US	5126291	A	30/06/92	US	4762942 A	09/08/88
				US	4883816 A	28/11/89
				US	4894367 A	16/01/90
				US	4981989 A	01/01/91
BE	1012546	A6	05/12/00	AU	1850500 A	24/07/00
				EP	1140444 A	10/10/01
WO	0100047	A1	04/01/01	AU	5719200 A	31/01/01
WO	0025764	A2	11/05/00	AU	6470999 A	22/05/00
				BR	9914815 A	03/07/01
				EP	1124548 A	22/08/01
EP	0781554	A1	02/07/97	US	5965615 A	12/10/99
				JP	3119430 B	18/12/00
				JP	10095731 A	14/04/98
				WO	9704767 A	13/02/97

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.